Structured evidence table for Mct Oil Cognitive Performance Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Mct Oil Cognitive Performance Randomized Trial | EK supplementation was associated with a statistically significant improvement in cognitive performance compared with placebo (SMD = 0.29, 95% CI 0.16-0.41; p p = 0.083), study duration (acute vs. | 1 | Bonnechère B (2026) | The effect of exogenous ketone bodies on cognition across health and disease: a systematic review and meta-analysis. |
| Mct Oil Cognitive Performance Randomized Trial | Discussion EK supplementation is associated with modest improvements in cognitive performance across diverse populations and study designs. | 1 | Bonnechère B (2026) | The effect of exogenous ketone bodies on cognition across health and disease: a systematic review and meta-analysis. |
| Mct Oil Cognitive Performance Randomized Trial | Introduction Cognitive function is closely linked to brain energy metabolism and may be compromised by aging, metabolic stress, and neuropsychiatric disease. | 1 | Bonnechère B (2026) | The effect of exogenous ketone bodies on cognition across health and disease: a systematic review and meta-analysis. |
| Mct Oil Cognitive Performance Randomized Trial | Ketone bodies can serve as an alternative cerebral fuel and may also exert signaling effects relevant to cognition. | 1 | Bonnechère B (2026) | The effect of exogenous ketone bodies on cognition across health and disease: a systematic review and meta-analysis. |
| Mct Oil Cognitive Performance Randomized Trial | The potential benefits of KD are explored across neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis, based on both preclinical and clinical evidence that supports its feasibility. | 4 | Salgueiro AM (2026) | Ketogenic diet as a therapeutic strategy for neurodegenerative diseases: from mechanisms to translational challenges. |
| Mct Oil Cognitive Performance Randomized Trial | This review underscores the potential of KD for treating neurodegeneration on the basis of current scientific evidence while highlighting the need for further research to optimize its application and address existing gaps. | 4 | Salgueiro AM (2026) | Ketogenic diet as a therapeutic strategy for neurodegenerative diseases: from mechanisms to translational challenges. |
| Mct Oil Cognitive Performance Randomized Trial | The ketogenic diet (KD) is increasingly recognized as a promising therapeutic strategy for neurodegenerative disorders because of its multifaceted impacts on key pathophysiological mechanisms. | 4 | Salgueiro AM (2026) | Ketogenic diet as a therapeutic strategy for neurodegenerative diseases: from mechanisms to translational challenges. |
| Mct Oil Cognitive Performance Randomized Trial | This review explores the molecular pathways through which KD may protect against neurodegeneration, including the use of ketone bodies as alternative energy substrates, reduction of oxidative stress and inflammation, modulation of autophagy and protein aggregation, and impact on the gut microbiome. | 4 | Salgueiro AM (2026) | Ketogenic diet as a therapeutic strategy for neurodegenerative diseases: from mechanisms to translational challenges. |
Source documents